RxDoctor Payments Data

Sudha Karupaiah, MD

Internal Medicine · San Jose, CANPI 1316984800

Payments from drug & device makers

$1,667in general payments, 2019–2025

Across 78 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$419
  • AstraZeneca$357
  • GSK$245
  • Jazz Pharmaceuticals Inc.$136
  • AbbVie$133
  • Eisai Inc.$98
  • plus $278 from 7 others

What the payments were for

  • Food & beverage$1,667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,667 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$268,856
Medicare patients
429
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$30,038
JanuviaSitagliptin Phosphate20$29,861
EliquisApixaban15$20,712
JardianceEmpagliflozin15$18,687
FarxigaDapagliflozin Propanediol12$16,067
XareltoRivaroxaban12$9,739
Breo ElliptaFluticasone/Vilanterol11$6,611
NexiumEsomeprazole Magnesium11$5,232
Levothyroxine Sodium210$2,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,751
Atorvastatin Calcium258$2,537
Albuterol Sulfate HfaAlbuterol Sulfate70$2,417
Losartan Potassium178$1,987
Wixela InhubFluticasone Propion/Salmeterol13$1,933
Glipizide ErGlipizide97$1,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$245$36,64931 claims
MerckJanuvia$96$29,86120 claims
AstraZenecaFarxiga, Nexium$357$21,29923 claims
Boehringer IngelheimJardiance$50$18,68715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →